Literature DB >> 12797868

The etiology and outcome of pneumonia in human immunodeficiency virus-infected children admitted to intensive care in a developing country.

Heather J. Zar1, Patti Apolles, Andrew Argent, Max Klein, John Burgess, David Hanslo, Eric D. Bateman, Greg Hussey.   

Abstract

In developing countries, many human immunodeficiency virus (HIV)-infected children require intensive care unit (ICU) resources for pneumonia, but there is little information on the etiology of pneumonia or the impact of ICU intervention.
OBJECTIVE: To compare the etiology and outcome of pneumonia in HIV-positive and seronegative children admitted to ICU.
DESIGN: Prospective study.
SETTING: Two pediatric ICUs linked to the University of Cape Town, South Africa. PATIENTS: Consecutive children admitted for pneumonia during 1998.
MEASUREMENTS AND MAIN RESULTS: Clinical, demographic, ventilatory, and laboratory data were collected. Blood for testing was obtained. Induced sputum or nondirected bronchoalveolar lavage was performed for culture and Pneumocystis carinii identification; gastric lavage (GL) provided specimens for mycobacterial culture. Seventy-six children (21 [27.6%, 95% confidence interval {CI} = 18-39.1] HIV-positive) were enrolled. At admission, HIV infection was diagnosed in 15 of the 21 (71.4% [47.8-88.7]) HIV-positive patients. P. carinii pneumonia occurred in eight HIV-positive children (38% of HIV-infected patients) and one HIV-negative child. It was the acquired immunodeficiency syndrome (AIDS)-defining illness in seven children (47%). The incidence of bacteremia (15.3%) was similar in HIV-positive (15.8%) and HIV-negative children (15.1%), p =.94; Streptococcus pneumoniae and Staphylococcus aureus were the predominant isolates. Bacterial and viral isolates from sputum or bronchoalveolar lavage, including Mycobacterium tuberculosis in six (8%) children, did not differ by HIV status. Intermittent positive pressure ventilation was used in 8 of 21 (38%) HIV-positive children and 28 of 55 (51%) HIV-negative children, p =.32. Median days of intermittent positive pressure ventilation (3 [2-6]), ICU (5 [3-9.5]), and hospital (11 [7.5-19]) did not vary by HIV status. The in-hospital mortality rate for HIV-positive children (6 of 21 [28.6%]) was double that for seronegative patients (8 of 55[14.5%], relative risk [RR] 1.96 [0.77-4.99], p =.16).
CONCLUSION: More than a quarter of children admitted to ICU for pneumonia in this geographic area are HIV-positive; most are diagnosed with HIV at admission. P. carinii pneumonia is a common AIDS indicator disease. HIV-infected children admitted with pneumonia had a worse outcome than seronegative children, a difference that is rendered statistically insignificant by the small sample size.

Entities:  

Year:  2001        PMID: 12797868     DOI: 10.1097/00130478-200104000-00003

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  11 in total

Review 1.  Procedures for collection of induced sputum specimens from children.

Authors:  Lindsay R Grant; Laura L Hammitt; David R Murdoch; Katherine L O'Brien; J Anthony Scott
Journal:  Clin Infect Dis       Date:  2012-04       Impact factor: 9.079

2.  Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia.

Authors:  Darlington M Mwenya; Bambos M Charalambous; Patrick P J Phillips; James C L Mwansa; Sarah L Batt; Andrew J Nunn; Sarah Walker; Diana M Gibb; Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

3.  Short-term mortality and implementation of antiretroviral treatment for critically ill HIV-infected children in a developing country.

Authors:  C Cowburn; M Hatherill; B Eley; J Nuttall; G Hussey; L Reynolds; Z Waggie; L Vivian; A Argent
Journal:  Arch Dis Child       Date:  2006-05-02       Impact factor: 3.791

4.  Diagnosis and management of community-acquired pneumonia in children: South African Thoracic Society guidelines.

Authors:  H J Zar; D P Moore; S Andronikou; A C Argent; T Avenant; C Cohen; R J Green; G Itzikowitz; P Jeena; R Masekela; M P Nicol; A Pillay; G Reubenson; S A Madhi
Journal:  Afr J Thorac Crit Care Med       Date:  2020-10-13

5.  23-valent pneumococcal polysaccharide vaccine elicits hierarchical antibody and cellular responses in healthy and tuberculosis-cured elderly, and HIV-1-infected subjects.

Authors:  Huichang Huang; Xiaohua Qian; Rong Pan; Ling Shen; Shanshan Liang; Feifei Wang; Peng Zhang; Hongbo Shen; Zheng W Chen
Journal:  Clin Immunol       Date:  2018-05-09       Impact factor: 3.969

6.  Children with human immunodeficiency virus admitted to a paediatric intensive care unit in the United Kingdom over a 10-year period.

Authors:  Sian Cooper; Hermione Lyall; Sam Walters; Gareth Tudor-Williams; Parviz Habibi; Claudine de Munter; Joseph Britto; Simon Nadel
Journal:  Intensive Care Med       Date:  2003-11-13       Impact factor: 17.440

7.  Managing HIV in the PICU--the experience at the Red Cross War Memorial Children's Hospital in Cape Town.

Authors:  A C Argent
Journal:  Indian J Pediatr       Date:  2008-08-31       Impact factor: 1.967

8.  Pneumocystis pneumonia in South African children diagnosed by molecular methods.

Authors:  Brenda M Morrow; Catherine M Samuel; Marco Zampoli; Andrew Whitelaw; Heather J Zar
Journal:  BMC Res Notes       Date:  2014-01-10

9.  Prevalence and correlates of treatment failure among Kenyan children hospitalised with severe community-acquired pneumonia: a prospective study of the clinical effectiveness of WHO pneumonia case management guidelines.

Authors:  Ambrose Agweyu; Minnie Kibore; Lina Digolo; Caroline Kosgei; Virginia Maina; Samson Mugane; Sarah Muma; John Wachira; Mary Waiyego; Elizabeth Maleche-Obimbo
Journal:  Trop Med Int Health       Date:  2014-08-14       Impact factor: 2.622

Review 10.  Pneumocystis jirovecii pneumonia in tropical and low and middle income countries: a systematic review and meta-regression.

Authors:  David M Lowe; Molebogeng X Rangaka; Fabiana Gordon; Chris D James; Robert F Miller
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.